<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2023-02-23T14:44:50Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9385668" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9385668</identifier>
        <datestamp>2022-08-19</datestamp>
        <setSpec>commbiol</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Commun Biol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Commun Biol</journal-id>
              <journal-title-group>
                <journal-title>Communications Biology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2399-3642</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9385668</article-id>
              <article-id pub-id-type="pmcid">PMC9385668</article-id>
              <article-id pub-id-type="pmc-uid">9385668</article-id>
              <article-id pub-id-type="pmid">35978153</article-id>
              <article-id pub-id-type="pmid">35978153</article-id>
              <article-id pub-id-type="publisher-id">3777</article-id>
              <article-id pub-id-type="doi">10.1038/s42003-022-03777-z</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7319-9685</contrib-id>
                  <name>
                    <surname>Brojakowska</surname>
                    <given-names>Agnieszka</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Kour</surname>
                    <given-names>Anupreet</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1512-6242</contrib-id>
                  <name>
                    <surname>Thel</surname>
                    <given-names>Mark Charles</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5609-4622</contrib-id>
                  <name>
                    <surname>Park</surname>
                    <given-names>Eunbee</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8826-4649</contrib-id>
                  <name>
                    <surname>Bisserier</surname>
                    <given-names>Malik</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Garikipati</surname>
                    <given-names>Venkata Naga Srikanth</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8108-7993</contrib-id>
                  <name>
                    <surname>Hadri</surname>
                    <given-names>Lahouaria</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mills</surname>
                    <given-names>Paul J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7580-2276</contrib-id>
                  <name>
                    <surname>Walsh</surname>
                    <given-names>Kenneth</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5270-5270</contrib-id>
                  <name>
                    <surname>Goukassian</surname>
                    <given-names>David A.</given-names>
                  </name>
                  <address>
                    <email>david.goukassian@mssm.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Cardiovascular Research Institute, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.27755.32</institution-id><institution-id institution-id-type="ISNI">0000 0000 9136 933X</institution-id><institution>Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, </institution><institution>University of Virginia School of Medicine, </institution></institution-wrap>Charlottesville, VA USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412332.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1545 0811</institution-id><institution>Dorothy M. Davis Heart Lung and Research Institute and Department of Emergency Medicine, </institution><institution>The Ohio State University Wexner Medical Center, </institution></institution-wrap>Columbus, OH USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Center of Excellence for Research and Training in Integrative Health, </institution><institution>University of California San Diego, </institution></institution-wrap>La Jolla, CA USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>17</day>
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>17</day>
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <volume>5</volume>
              <elocation-id>828</elocation-id>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s) 2022, corrected publication 2022</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleâs Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleâs Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">With planned deep space and commercial spaceflights, gaps remain to address health risks in astronauts. Multiple studies have shown associations between clonal expansion of hematopoietic cells with hematopoietic malignancies and cardiometabolic disease. This expansion of clones in the absence of overt hematopoietic disorders is termed clonal hematopoiesis (CH) of indeterminate potential (CHIP). Using deep, error-corrected, targeted DNA sequencing we assayed for somatic mutations in CH-driver genes in peripheral blood mononuclear cells isolated from de-identified blood samples collected from 14 astronauts who flew Shuttle missions between 1998â2001. We identified 34 nonsynonymous mutations of relatively low variant allele fraction in 17 CH-driver genes, with the most prevalent mutations in <italic>TP53</italic> and <italic>DNMT3A</italic>. The presence of these small clones in the blood of relatively young astronaut cohort warrants further retrospective and prospective investigation of their clinical relevance and potential application in monitoring astronautâs health.</p>
              </abstract>
              <abstract id="Abs2" abstract-type="web-summary">
                <p id="Par2">Deep targeted DNA sequencing of peripheral blood mononuclear cells isolated from blood samples from 14 astronauts who flew Shuttle missions between 1998â2001 identifies 34 non-silent mutations, predominantly in TP53 and DNMT3A.</p>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Risk factors</kwd>
                <kwd>Predictive markers</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000104</institution-id>
                      <institution>National Aeronautics and Space Administration (NASA)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>80NSSC19K1079</award-id>
                  <award-id>80NSSC21K0549</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Goukassian</surname>
                      <given-names>David A.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>TRISH is the Translational Research Institute for Space Health which is a subbranch of the National Aeronautics and Space Administration.</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>Â© The Author(s) 2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p id="Par3">With the advent of NASAâs deep space Gateway and Artemis missions and the expansion of commercial spaceflights, there is an increased need to understand, counteract, and mitigate health risks associated with spaceflight. Specific acute and long-term adverse effects and risks inherent to space missions are defined not only by duration, but also the course of flight, i.e., remaining in low Earth orbit (LEO) where Earthâs magnetic field provides shielding from space radiation or going beyond this protective shield into deep space. Some of these adverse effects include bone-density loss, neurovestibular changes and muscle atrophy. In addition, there are degenerative risks, including space radiation (IR)-induced cancer, cardiovascular and neurodegenerative diseases<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>, and all three are priority risk reduction areas identified by NASAâs Human Research Roadmap. Thus, quality health assessments for astronauts that account for an individualâs susceptibility are critical for understanding and addressing risks before, during and after future exploration-type, deep-space missions. Considering baseline genetic and extrinsic variability, the development of tools that permit the assessment of individual genetic susceptibility would improve risk stratification and long-term clinical management.</p>
              <p id="Par4">Somatic mutations occur randomly and in response to various systemic and environmental stressors. While most mutations do not affect cell phenotype, others alter the cellâs fitness, conferring a selective proliferative and survival advantage leading to clonal events in normal tissues. Clonal hematopoiesis (CH) is the expansion of such clones in hematopoietic stem/progenitor cells (HSPCs), resulting in a relatively benign precursor state. The presence of these clonal mutations in the absence of neoplasia at aâ&gt;2% variant allele frequency (VAF) is designated as CH of indeterminate potential (CHIP)<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. The accumulation of somatic mutations occurs as a function of aging and can be facilitated by inflammatory alterations in the microenvironment. However, other mechanisms promoting clonal progression remain unclear. Most mutations associated with age-related CHIP occur in epigenetic modifier genes (<italic>DNMT3A, TET2, ASXL1</italic>)<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>. In contrast to age-related CHIP, there is an accelerated form of CH that is found in cancer survivors who have been exposed to therapy with genotoxic agents. This is referred to as therapy-associated clonal hematopoiesis (t-CH) and mutations occur predominantly in genes involved in DNA damage response (DDR) pathway (<italic>TP53, PPM1D</italic>)<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Studies have associated CHIP with an increased risk of hematological and solid malignancies, cardiovascular disease (CVD), cardiometabolic and neurodegenerative disease, and overall higher mortality<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. Notably, the size of mutant clones is associated with increased risk; however, additional factors such as comorbidities or cell-extrinsic factors, are likely to impact the degree of risk for such outcomes. Additionally, experimental studies have shown that CH can contribute to chronic diseases by promoting inflammation<sup><xref ref-type="bibr" rid="CR8">8</xref>â<xref ref-type="bibr" rid="CR10">10</xref></sup>.</p>
              <p id="Par5">Spaceflights are associated with exposure to various stressors, including IR, microgravity, and other harmful space environmental factors. NASAâs Twin study reported hematopoietic mutations in <italic>DNMT3A</italic> and <italic>TET2</italic>, consistent with the presence of CHIP<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. While the Twin studies employed conventional next generation, whole genome sequencing, the current study employed deep, error-corrected DNA sequencing to detect somatic mutations in CH-driver genes using de-identified blood samples collected from 14 astronauts who flew Space Transportation System (STS), aka Space Shuttle, missions between 1998â2001. We identified 34 non-silent mutations, predominantly in <italic>TP53</italic> and <italic>DNMT3A</italic>, consistent with the presence of CH in this relatively young astronaut cohort.</p>
            </sec>
            <sec id="Sec2" sec-type="results">
              <title>Results</title>
              <p id="Par6">We obtained de-identified whole blood samples from 14 astronauts who flew relatively short Space Shuttle missions (median 12 days) between 1998â2001. These samples were stored at â80âÂ°C for ~20 years. Blood samples were collected 10 days before flight, the day of landing, and 3 days after landing<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. However, for this specific study, only samples from 3 days after landing (Râ+â3) were collected as buffy coats (peripheral blood mononuclear cells - PBMCs). The median age of the Shuttle mission crew (including individuals who did not donate blood) at sample collection was approximately 42 years (IQRâ=â39â45) (Fig.Â <xref rid="Fig1" ref-type="fig">1a</xref>). Six of the 14 (43%) astronauts were on their first mission at time of sample collection. Approximately 85% of crew members were male during missions conducted between 1998â2001. An average of two extravehicular activities (EVAs) occurred per Shuttle mission, with two astronauts participating per EVA (an average of four astronauts per mission). Per the Lifetime Surveillance of Astronaut Health (LSAH) at NASA Johnson Space Center, the astronauts who participated in the following study did not have any prior exposures to chemotherapy or radiation therapy. To detect somatic mutations in CH-driver genes in PBMCs, we performed deep, error-corrected DNA sequencing using a myeloid panel to enrich 37 candidates frequently mutated in myeloid malignancies. Mutational analysis of PBMCs identified 34 somatic nonsynonymous single nucleotide variants (SNVs) in 17 genes at 0.10â0.95% (median 0.18%) VAF (Fig.Â <xref rid="Fig1" ref-type="fig">1a, d</xref>). Five out of 14 astronauts (36%) harbored two or more mutations. Subjects C68 and C21 harbored the largest number of clonal SNVs, 12 and 5, respectively (Fig.Â <xref rid="Fig1" ref-type="fig">1b</xref>). We detected 27 missense SNVs (median VAF 0.18%), 4 nonsense SNVs (median VAF 0.14%), 2 splicing SNVs (median VAF 0.53%), and 1 frameshift SNV (Fig.Â <xref rid="Fig1" ref-type="fig">1b, d</xref>). The most common exonic substitution was cytosine to thymine (CâââT) transition, followed by guanine to adenine (GâââA) transition (Fig.Â <xref rid="Fig1" ref-type="fig">1c</xref>), which is considered a mutational signature of aging<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> and is common in variants associated with CHIP.<fig id="Fig1"><label>Fig. 1</label><caption><title>Characteristics of Clonal Hematopoiesis (CH) Mutations.</title><p><bold>a</bold> We identified somatic mutations in known clonal hematopoiesis of indeterminate potential (CHIP) driver genes using peripheral blood mononuclear cells isolated from 14 astronauts who flew short space Shuttle missions lasting a median of 12 days between 1998â2001. Created with BioRender.com. <bold>b</bold> Number of somatic nonsynonymous single nucleotide variants (SNVs) in CHIP-driver genes harbored per subject. <bold>c</bold> Rates of different substitution types observed in clonal SNVs. Only one guanine to thymine transition was observed. <bold>d</bold> Density of mutations by VAF for each mutation type.</p></caption><graphic xlink:href="42003_2022_3777_Fig1_HTML" id="d32e473"/></fig></p>
              <p id="Par7">We detected variants in 17 of the 37 genes represented in the panel. The most commonly mutated gene was <italic>TP53</italic> (7 variants) followed by <italic>DNTM3A</italic> (6 variants) accounting for 38% of mutations detected (Fig.Â <xref rid="Fig2" ref-type="fig">2a</xref>). One subject, C12, harbored the <italic>JAK2</italic> V617F mutation (VAF 0.82%) (Fig.Â <xref rid="Fig2" ref-type="fig">2b, c</xref>), a clinically relevant variant identified in myeloproliferative neoplasms (MPNs) that has also been associated with ~12-fold increased risk of CVD and thrombosis risk<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR14">14</xref>â<xref ref-type="bibr" rid="CR17">17</xref></sup>. Subject C68 had a single <italic>PHF6</italic> SNV with a VAF of 0.95% (Fig.Â <xref rid="Fig2" ref-type="fig">2b, c</xref>), representing the largest variant clone detected by this analysis. While the pathogenicity of this mutation is unclear, <italic>PHF6</italic> variants are frequently detected in patients with hematopoietic malignancies<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Multiple mutations in <italic>TP53</italic> and <italic>PTPN11</italic> were also identified in subject C68, and four other subjects harbored co-mutations in other CH-driver genes (Fig.Â <xref rid="Fig2" ref-type="fig">2c</xref>). All <italic>TP53</italic> SNVs missense mutations occurred in the DNA binding domain. Two mutations were located in the <italic>TP53</italic> mutation hotspots: Arg248Gln (VAF 0.27%) and His179Arg (VAF 0.25%) (Fig.Â <xref rid="Fig3" ref-type="fig">3a</xref>), which are implicated in various cancers<sup><xref ref-type="bibr" rid="CR19">19</xref>â<xref ref-type="bibr" rid="CR21">21</xref></sup>. Six out of 14 astronauts (43%) had at least 1 <italic>TP53</italic> SNV (average VAF 0.20%), of which subject C68 had two missense mutations (Fig.Â <xref rid="Fig2" ref-type="fig">2c</xref>). In comparison, 5/14 (36%) of astronauts had at least one <italic>DNMT3A</italic> SNV, which were predominantly missense mutations in the methyltransferase domain, thus likely impacting enzyme function, or nonsense mutations (Arg771Ter, Trp305Ter) that had been identified in patients with aplastic anemia and angioimmunoblastic T Cell lymphoma<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup> (Fig.Â <xref rid="Fig3" ref-type="fig">3b</xref>). Subject C21 had two <italic>DNMT3A</italic> SNVs with 1 missense and 1 frameshift variant (Fig.Â <xref rid="Fig2" ref-type="fig">2c</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Clonal Hematopoiesis (CH) Profile of Astronauts.</title><p><bold>a</bold> Mutational profile of 17 known mutated CHIP-driver genes and number of astronauts with mutations in each gene. <bold>b</bold> Table with average VAF, noted nucleotide (BPÎ) and amino acid (AAÎ) changes for each nonsynonymous mutation. Asterix (*) refers to terminated sequencing for stop gain mutations while backslash (/) corresponds to splicing mutations where AAÎ is not applicable. <bold>c</bold> Mutation plot for each individual is represented as columns. Each rectangle represents number of mutations identified in each gene, with black being 1 mutation and red 2 mutations, along with individual VAF (%) for each variant.</p></caption><graphic xlink:href="42003_2022_3777_Fig2_HTML" id="d32e586"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><title>Profile of nonsynonymous mutations for TP53 and DNMT3A.</title><p>Mapping of nonsynonymous mutations in (<bold>a</bold>) TP53 and (<bold>b</bold>) DNMT3A through Loliplot visualization. Clinically relevant hotspots are identified (red dots). Asterix (*) in mutations corresponds to sequence termination in stop gain mutations. <italic>P53_TAD: p53 transactivation domain; PWWP: Pro-Trp-Trp_Pro domain</italic>.</p></caption><graphic xlink:href="42003_2022_3777_Fig3_HTML" id="d32e606"/></fig></p>
            </sec>
            <sec id="Sec3" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par8">The advancement of error-corrected DNA sequencing technology permits the assessment of somatic mutations (at lower VAF) in CH-driver genes associated with increased risk of hematologic and non-hematologic cancers as well as cardiovascular diseases<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. This study used PBMCs collected ~20 years ago from 14 relatively young astronauts who flew space Shuttle missions between 1998â2001 to identify, retrospectively, somatic mutations in CH-driver genes.</p>
              <p id="Par9">We identified 34 nonsynonymous SNVs in 17 known CH-driver genes, of which <italic>TP53</italic> and <italic>DNMT3A</italic> were the most frequent. Notably, clone size was small, ranging from 0.10% to 0.95% VAF, and thus did not achieve the technical threshold to be considered as CHIP. In contrast, a population-based CH study of middle-aged participants (median age 58 years, range 19 to 108) showed that the most frequent variants occur in epigenetic modifier genes <italic>DNMT3A</italic>, followed by <italic>TET2</italic>, <italic>ASXL1</italic>, and <italic>TP53</italic><sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. However, the DDR gene <italic>TP53</italic> was the most frequently mutated in this astronaut cohort (median age 44 years, range 37â67), reflecting a potential difference compared to the civilian population<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>. Somatic <italic>TP53</italic> mutations are uncommon in patients without a history of cancer therapy<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. <italic>TP53</italic> encodes tumor suppressor p53 that is induced by various stress stimuli, including UV IR, DNA double-stranded breaks, and oxidative stress. <italic>TP53</italic> coordinates the transcription of genes involved in DNA damage repair, apoptosis, growth arrest, or senescence, and the dysregulation of p53 poses a risk for developing cancers, CVD, and other metabolic disorders<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. While the clones identified in this astronaut cohort are relatively small, there is a possibility for increased clonal instability with aging that may be facilitated by co-mutations in other driver genes. Indeed, 5/14 astronauts harbored mutations in at least two CH-driver genes, and subject C68 had variants in the four mutated genes. While we cannot assess the pathogenic risk and the clinical value for each small clone mutation, it provides a rationale for longitudinal studies to determine which clones are at high risk of transformation and then to develop strategies to inhibit their expansion at early stages.</p>
              <p id="Par10">Due to the lack of longitudinal samples and small sample size, conclusions regarding the implications of observed lesions remain limited, and further studies are required to assess the penetrance of these clones. Van Egeren et al. showed single HSPCs acquired <italic>JAK2-</italic>V617F mutations decades before the development of MPNs, with clonal growth and/or extinction often fluctuating years after mutation acquisition<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. While the initial occurrence of these CH lesions within our astronaut cohort cannot be ascertained, the spaceflight environment introduces considerable physiological stress, which could temporally alter clonal dynamics. Our team recently showed plasma cell-free mitochondrial DNA (cf-mtDNA) and 8-OHdG levels were elevated in these astronauts 3 days post-flight (Râ+â3) and found inflammatory (<italic>TNFÎ±, IL-1Î±, IL-1Î²</italic>), oxidative stress (<italic>SOD1, GPX1, NOX4, SERPINE1, HMOX1</italic>), and DNA damage (<italic>OGG1, PARP-1</italic>) markers were significantly upregulated at Râ+â3 compared to baseline (10 days before flight) in isolated PBMCs<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, suggesting spaceflight contributes to significant physiological stress, which may be an impetus for clonal selection and expansion. While we cannot ascertain which isolated space environment factor may pose considerable risks for CH development, considering the clonal landscape in the following astronaut cohort bares closer resemblance to t-CH, it is possible space IR may be a primary driver of clonal selection. Space IR comprises of high charge and energy (HZE) ions with a high linear energy transfer (LET) and provides different energy deposition patterns in cells creating densely ionizing tracks that generate clustered DNA damage compared to low LET terrestrial IR. Prior studies examining the risk of cataracts following space IR exposure during Shuttle missions noted several thousand high-LET particles (LETâ&gt;â30âkeV/Âµm) pass through the lens with an average scaled mission lens dose of 73.5âmSv (0.07âGy) for missions of 10 to 14-day duration<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. Additionally, astronauts within the studied cohort embarked on EVAs during their Shuttle mission which also modifies degree of stressor exposure. While most EVAs are scheduled around solar activity, most galactic cosmic rays (GCRs) are unpredictable, and spacesuit radiation shielding alone may not be enough to mitigate radiation exposure and its associated risks<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Considering cancer patients receiving external beam radiation therapy exhibit pronounced CH mutations in DDR genes (<italic>TP53, CHEK2, PPM1D</italic>) along with faster clone growth following cumulative exposure<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, it can be postulated that exposure to space IR may alter the fitness landscape of observed CH mutations and warrants further investigation. Additionally, the effect of sex on CH dynamics should be considered as approximately 85% of crew members in Shuttle Missions from 1998â2001 were male. Prior studies have shown the male sex acquired more somatic mutations with higher allele burdens in known CH-drivers such as <italic>JAK2, ASXL1, SRSF2, U2AF1</italic>, and <italic>IDH1/2</italic> and were associated with overall poorer clinical outcomes<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Thus, more comprehensive studies are required to ascertain whether sex modifies space environment-induced CH risk using a more diverse cohort.</p>
              <p id="Par11">Overall, further longitudinal studies are required to characterize CH and somatic mutational profiles in the context of space flight-associated stressors and their associated clinical impact. To date, there is no evidence of relevant CVD, cancer, or neurodegenerative diagnoses associated with this given astronaut cohort (current median age 62.5 years (IQR 60â67)). The lack of longitudinal samples from these same astronauts limits the assessment of clone stability, pathogenic potential, and prognostic value. Studies of CH in astronauts would provide a new tool for assessing individual risk and potentially optimize long-term health monitoring. Additional analyses would also offer an opportunity to address the paucity of longitudinal CH studies using a unique cohort of physically fit individuals and provide more insights into factors that influence CH in the general population. Thus, this study serves to address the feasibility of using bio-banked astronaut samples and demonstrate the importance of collaborations between NASAâs Human Research Program, Translational Research Institute for Space Health, Space Biology Program, NASAâs clinical support teams and corresponding data and biorepository branches, and NASA IRB to facilitate retrospective and prospective longitudinal studies by increasing sample availability (while protecting health information (PHI) and maintaining HIPAA regulations). This integration of clinical data could optimize the value of CHIP studies for the assessment of lifetime risks before and after spaceflight.</p>
            </sec>
            <sec id="Sec4">
              <title>Methods</title>
              <sec id="Sec5">
                <title>Subjects and samples</title>
                <p id="Par12">We obtained de-identified whole blood samples from 14 astronauts who flew relatively short (median 12 day long) space Shuttle missions, between 1998â2001. Identifying information related to these samples is limited to the crewâs binned age in order to ensure privacy of involved personnel (Fig.Â <xref rid="Fig1" ref-type="fig">1a</xref>). De-identified aliquots of 14 peripheral blood mononuclear cell (PBMC) samples, isolated from blood samples 3 days after return (Râ+â3; during original study in 1998â2001; note, the buffy coats to obtain PBMCs were collected only at this time point), were prepared and shipped overnight to the University of Virginia School of Medicine for detection of somatic mutations involved in known CHIP-driver genes (Fig.Â <xref rid="Fig1" ref-type="fig">1a</xref>). Given that samples are de-identified and targeted DNA sequencing would not permit individual identification, NASAâs Institutional Review Board (IRB) deemed this study non-human research (STUDY00000075) and the Icahn School of Medicine at Mount Sinaiâs IRB deemed this study as exempt (HSM19-00367). Blood samples were collected during a NASA flight study; astronauts provided written informed consent to participate in that study and have blood stored and used for residual analyses<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>.</p>
              </sec>
              <sec id="Sec6">
                <title>Sample preparation and targeted DNA sequencing</title>
                <p id="Par13">Genomic DNA was isolated from PBMCs from each sample using the QIAamp DNA Blood Mini kit (Cat #51104). DNA quality was assessed using the PreSeq QC kit (Cat # SA0597 and SA0598) provided by ArcherDX (now Invitae) using real-time polymerase chain reaction (RT-PCR). ArcherDX VariantPlex core myeloid kit with 37 genes panel (Supplementary TableÂ <xref rid="MOESM1" ref-type="media">1</xref>) was used to perform target specific PCR using Anchored Multiplex PCR (AMPâ¢) chemistry to add specific Molecular Barcodes (MBC) and indexes. DNA libraries were prepared using Archer Library Preparation Reagents for Illumina (Cat #AB0101) by following the manufacturerâs protocol. Library sequencing was performed using Illumina NextSeq platform with high output kits as per manufacturer guidelines to generate 150âbp; paired end data. Sequencing was performed to 15000X average coverage. NGS data was analyzed using the Archer Analysis software (<ext-link ext-link-type="uri" xlink:href="https://analysis.archerdx.com/">https://analysis.archerdx.com/</ext-link>) including the following steps. Raw paired end FASTQ files were subjected to read cleaning and adaptor trimming to remove adapter sequences and low-quality portions of reads at 5â and 3â ends. Then unique reads / read pairs were grouped together into âmolecular binsâ, according to molecular barcode and index sequences. Bins were subjected to deduplication and error correction to create a consensus read for each bin. A combination of bowtie2 and BWA-MEM was used to map reads against the reference human genome (hg19/GCRh37). Generated variants were annotated with Ensembl Variant Effect Predictor.</p>
                <p id="Par14">Variants (SNP/ InDel) generated with this method were compared with a normal dataset using Archerâs analysis pipeline to distinguish noise from a true call. The normal dataset was created with sequencing data from seven young, healthy individuals. Based on the frequency at which a variant is observed in the normal dataset, the noise distribution at each variant call was calculated. Then the probability was calculated for the observed variant AF that could have been generated by noise given that noise distribution. Low normal data set AF outlier <italic>p</italic> value indicated that a variant was unlikely to have been generated by noise.</p>
                <p id="Par15">A maximum VAF threshold of 0.40 was used to exclude potential germline mutation from variant calling. Below this threshold, variants were further filtered if (1) AF outlier <italic>p</italic>ââ¤â0.01; (2) GenomeAD frequencyââ¤â0.05; (3) no previous report of the variant identified in Catalog of Somatic Mutations in Cancer or ClinVar; (4) duplicate variant per sample. The final data set is available in Supplementary DataÂ <xref rid="MOESM3" ref-type="media">1</xref>.</p>
              </sec>
              <sec id="Sec7">
                <title>Statistics and reproducibility</title>
                <p id="Par16">Due to limited sample availability, there is no replicate for the sequencing. Strict criteria for sequencing data quality check were applied to each sample. All the samples passed the QC status that is determined by the Invitae (Archer) data analysis pipeline (<ext-link ext-link-type="uri" xlink:href="https://analysis.archerdx.com/">https://analysis.archerdx.com/</ext-link>). Statistical evaluation for sequencing data from each sample is presented in Supplementary DataÂ <xref rid="MOESM4" ref-type="media">2</xref>. As stated above, only true somatic variants were selected by applying the strict filtering criteria of AF outlier <italic>p</italic>ââ¤â0.01, present in COSMIC and GenomeAD AFââ¤â0.05. Binomial distribution was used to model the noise at each position from the sequencing data of the normal data set to generate the AF outlier <italic>p</italic>-value. The background noise model was established using these steps: (i) Identified base changes with unusually high AF and exclude them using Inter Quantile Range (IQR) filtering. (ii) For remaining variants: (a) Background noiseâ=âSum of all AOs (Alternate observations) (across all samples)/Sum of depth (across all samples) at a given position, on per base change basis. If AOâ=â0, background noise was assumed to be 1/Sum of the depth (across all samples). (b) The background noise calculated in (A) became the expected rate of AO observations per unique molecule at a given position. This rate was used as the â<italic>p</italic>â term in a binomial distribution. (c) For a given variant, analysis can calculate a <italic>p</italic> value which expresses the probability that the noise model for that variant would generate the observed AF or greater. This assumes a binomial distribution with <italic>p</italic>â=âbackground noise and <italic>n</italic>â=âdepth of coverage for that variant, which computes the probability of the null hypothesis (<italic>p</italic>-value). The null hypothesis was that the number of alternate observations seen are due to the background error that was estimated. (d) Any variant that had a low <italic>p</italic>-value was considered a significant variant. (The recommended default <italic>p</italic>-value cutoff, or alpha, is 0.01, but this can be adjusted based on tolerance for false positives and false negatives).</p>
              </sec>
              <sec id="Sec8">
                <title>Reporting summary</title>
                <p id="Par17">Further information on research design is available in theÂ <xref rid="MOESM5" ref-type="media">Nature Research Reporting Summary</xref> linked to this article.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary information</title>
              <sec id="Sec9">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="42003_2022_3777_MOESM1_ESM.pdf">
                      <caption>
                        <p>Supplementary Information</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM2">
                    <media xlink:href="42003_2022_3777_MOESM2_ESM.pdf">
                      <caption>
                        <p>Description of Additional Supplementary Data</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM3">
                    <media xlink:href="42003_2022_3777_MOESM3_ESM.xlsx">
                      <caption>
                        <p>Supplementary Data 1</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM4">
                    <media xlink:href="42003_2022_3777_MOESM4_ESM.xlsx">
                      <caption>
                        <p>Supplementary Data 2</p>
                      </caption>
                    </media>
                  </supplementary-material>
                  <supplementary-material content-type="local-data" id="MOESM5">
                    <media xlink:href="42003_2022_3777_MOESM5_ESM.pdf">
                      <caption>
                        <p>Reporting Summary</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p><bold>Publisherâs note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
              <fn>
                <p>These authors contributed equally: Agnieszka Brojakowska, Anupreet Kour.</p>
              </fn>
              <fn>
                <p>
                  <bold>Change history</bold>
                </p>
                <p>10/10/2022</p>
                <p>A Correction to this paper has been published: 10.1038/s42003-022-04071-8</p>
              </fn>
            </fn-group>
            <sec>
              <title>Supplementary information</title>
              <p>The online version contains supplementary material available at 10.1038/s42003-022-03777-z.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>We would like to thank the Lifetime Surveillance of Astronaut Health (LSAH) at NASA Johnson Space Center for their assistance with mission information and manuscript review. This work is supported by the Translational Research Institute for Space Health through NASA Cooperative Agreement NNX16AO69A â FIP0005, National Aeronautics and Space Administration Human Research Program Space Biology Element grant 80NSSC19K1079 (to Dr. Goukassian), and National Aeronautics and Space Administration Human Research Program Space Biology Element grant 80NSSC21K0549 (to Drs. Goukassian and Walsh).</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>A.B., A.K., K.W., P.M., D.A.G. are responsible for conceptualization of this study. A.B., A.K., M.C.T., E.P. are responsible for study design, carried out experiments, and data analysis. A.B., A.K., M.C.T., E.P., K.W., D.A.G. carried out data interpretation. A.B., M.B., D.A.G. were responsible for data visualization. A.B., D.A.G. wrote the original draft. A.B., A.K., M.C.T., E.P., P.M., M.B., V.N.S.G., L.H., K.W., D.A.G. contributed to paper preparation. All authors have given approval to the final version of the paper.</p>
            </notes>
            <notes notes-type="peer-review">
              <title>Peer review</title>
              <sec id="FPar1">
                <title>Peer review information</title>
                <p id="Par18"><italic>Communications Biology</italic> thanks Mrinal Patnaik, Juan Bautista Menendez-Gonzalez and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Kaoru Ito and Christina Karlsson-Rosenthal.</p>
              </sec>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>All data derived from analysis of clinical sequencing data (CH mutations) for all astronauts necessary to replicate the findings in the article are available within the main text and supplementary materials. The raw sequencing data for the astronaut cohorts are protected and are not broadly available due to privacy laws. The LSDA provides an appropriate process for archival of experimental data and dissemination, which complies with policies to govern sensitive data in accordance with NASA Human Research Program and Johnson Space Center (JSC) Institutional Review Board direction. Raw data elements may be requested from david.goukassian@mssm.edu with appropriate institutional approvals.</p>
            </notes>
            <notes id="FPar2" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par19">The authors declare no competing interests.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cucinotta</surname>
                      <given-names>FA</given-names>
                    </name>
                  </person-group>
                  <article-title>Space radiation risks for astronauts on multiple International Space Station missions</article-title>
                  <source>PLoS One</source>
                  <year>2014</year>
                  <volume>9</volume>
                  <fpage>e96099</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0096099</pub-id>
                  <pub-id pub-id-type="pmid">24759903</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stepanek</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Blue</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Parazynski</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Space Medicine in the Era of Civilian Spaceflight</article-title>
                  <source>N. Engl. J. Med</source>
                  <year>2019</year>
                  <volume>380</volume>
                  <fpage>1053</fpage>
                  <lpage>1060</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMra1609012</pub-id>
                  <pub-id pub-id-type="pmid">30865799</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Steensma</surname>
                      <given-names>DP</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical Implications of Clonal Hematopoiesis</article-title>
                  <source>Mayo Clin. Proc.</source>
                  <year>2018</year>
                  <volume>93</volume>
                  <fpage>1122</fpage>
                  <lpage>1130</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.mayocp.2018.04.002</pub-id>
                  <pub-id pub-id-type="pmid">30078412</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jaiswal</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Age-related clonal hematopoiesis associated with adverse outcomes</article-title>
                  <source>N. Engl. J. Med</source>
                  <year>2014</year>
                  <volume>371</volume>
                  <fpage>2488</fpage>
                  <lpage>2498</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1408617</pub-id>
                  <pub-id pub-id-type="pmid">25426837</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jaiswal</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease</article-title>
                  <source>N. Engl. J. Med</source>
                  <year>2017</year>
                  <volume>377</volume>
                  <fpage>111</fpage>
                  <lpage>121</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1701719</pub-id>
                  <pub-id pub-id-type="pmid">28636844</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coombs</surname>
                      <given-names>CC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes</article-title>
                  <source>Cell Stem Cell</source>
                  <year>2017</year>
                  <volume>21</volume>
                  <fpage>374</fpage>
                  <lpage>382.e374</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.stem.2017.07.010</pub-id>
                  <pub-id pub-id-type="pmid">28803919</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ogawa</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Horitani</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Izumiya</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Sano</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Somatic Mosaicism in Biology and Disease</article-title>
                  <source>Annu Rev. Physiol.</source>
                  <year>2022</year>
                  <volume>84</volume>
                  <fpage>113</fpage>
                  <lpage>133</lpage>
                  <pub-id pub-id-type="doi">10.1146/annurev-physiol-061121-040048</pub-id>
                  <pub-id pub-id-type="pmid">34637327</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fuster</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice</article-title>
                  <source>Science</source>
                  <year>2017</year>
                  <volume>355</volume>
                  <fpage>842</fpage>
                  <lpage>847</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.aag1381</pub-id>
                  <pub-id pub-id-type="pmid">28104796</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sano</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1beta/NLRP3 Inflammasome</article-title>
                  <source>J. Am. Coll. Cardiol.</source>
                  <year>2018</year>
                  <volume>71</volume>
                  <fpage>875</fpage>
                  <lpage>886</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jacc.2017.12.037</pub-id>
                  <pub-id pub-id-type="pmid">29471939</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fuster</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>TET2-Loss-of-Function-Driven Clonal Hematopoiesis Exacerbates Experimental Insulin Resistance in Aging and Obesity</article-title>
                  <source>Cell Rep.</source>
                  <year>2020</year>
                  <volume>33</volume>
                  <fpage>108326</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.celrep.2020.108326</pub-id>
                  <pub-id pub-id-type="pmid">33113366</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mencia-Trinchant</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clonal Hematopoiesis Before, During, and After Human Spaceflight</article-title>
                  <source>Cell Rep.</source>
                  <year>2020</year>
                  <volume>33</volume>
                  <fpage>108458</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.celrep.2020.108458</pub-id>
                  <pub-id pub-id-type="pmid">33242405</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mills</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Perez</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Adler</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Ziegler</surname>
                      <given-names>MG</given-names>
                    </name>
                  </person-group>
                  <article-title>The effects of spaceflight on adrenergic receptors and agonists and cell adhesion molecule expression</article-title>
                  <source>J. Neuroimmunol.</source>
                  <year>2002</year>
                  <volume>132</volume>
                  <fpage>173</fpage>
                  <lpage>179</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0165-5728(02)00313-2</pub-id>
                  <pub-id pub-id-type="pmid">12417448</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alexandrov</surname>
                      <given-names>LB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Signatures of mutational processes in human cancer</article-title>
                  <source>Nature</source>
                  <year>2013</year>
                  <volume>500</volume>
                  <fpage>415</fpage>
                  <lpage>421</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature12477</pub-id>
                  <pub-id pub-id-type="pmid">23945592</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 (V617F) Mice</article-title>
                  <source>Circ. Res</source>
                  <year>2018</year>
                  <volume>123</volume>
                  <fpage>e35</fpage>
                  <lpage>e47</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.313283</pub-id>
                  <pub-id pub-id-type="pmid">30571460</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Muendlein</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease</article-title>
                  <source>Am. J. Hematol.</source>
                  <year>2015</year>
                  <volume>90</volume>
                  <fpage>E17</fpage>
                  <lpage>E21</lpage>
                  <pub-id pub-id-type="doi">10.1002/ajh.23874</pub-id>
                  <pub-id pub-id-type="pmid">25345590</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cordua</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population</article-title>
                  <source>Blood</source>
                  <year>2019</year>
                  <volume>134</volume>
                  <fpage>469</fpage>
                  <lpage>479</lpage>
                  <pub-id pub-id-type="doi">10.1182/blood.2019001113</pub-id>
                  <pub-id pub-id-type="pmid">31217187</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nielsen</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Birgens</surname>
                      <given-names>HS</given-names>
                    </name>
                    <name>
                      <surname>Nordestgaard</surname>
                      <given-names>BG</given-names>
                    </name>
                    <name>
                      <surname>Kjaer</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Bojesen</surname>
                      <given-names>SE</given-names>
                    </name>
                  </person-group>
                  <article-title>The JAK2 V617F somatic mutation, mortality and cancer risk in the general population</article-title>
                  <source>Haematologica</source>
                  <year>2011</year>
                  <volume>96</volume>
                  <fpage>450</fpage>
                  <lpage>453</lpage>
                  <pub-id pub-id-type="doi">10.3324/haematol.2010.033191</pub-id>
                  <pub-id pub-id-type="pmid">21160067</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kurzer</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Weinberg</surname>
                      <given-names>OK</given-names>
                    </name>
                  </person-group>
                  <article-title>PHF6 Mutations in Hematologic Malignancies</article-title>
                  <source>Front Oncol.</source>
                  <year>2021</year>
                  <volume>11</volume>
                  <fpage>704471</fpage>
                  <pub-id pub-id-type="doi">10.3389/fonc.2021.704471</pub-id>
                  <pub-id pub-id-type="pmid">34381727</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Olivier</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hollstein</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hainaut</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>TP53 mutations in human cancers: origins, consequences, and clinical use</article-title>
                  <source>Cold Spring Harb. Perspect. Biol.</source>
                  <year>2010</year>
                  <volume>2</volume>
                  <fpage>a001008</fpage>
                  <pub-id pub-id-type="doi">10.1101/cshperspect.a001008</pub-id>
                  <pub-id pub-id-type="pmid">20182602</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sabapathy</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lane</surname>
                      <given-names>DP</given-names>
                    </name>
                  </person-group>
                  <article-title>Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others</article-title>
                  <source>Nat. Rev. Clin. Oncol.</source>
                  <year>2018</year>
                  <volume>15</volume>
                  <fpage>13</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrclinonc.2017.151</pub-id>
                  <pub-id pub-id-type="pmid">28948977</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chang</surname>
                      <given-names>MT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity</article-title>
                  <source>Nat. Biotechnol.</source>
                  <year>2016</year>
                  <volume>34</volume>
                  <fpage>155</fpage>
                  <lpage>163</lpage>
                  <pub-id pub-id-type="doi">10.1038/nbt.3391</pub-id>
                  <pub-id pub-id-type="pmid">26619011</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kulasekararaj</surname>
                      <given-names>AG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome</article-title>
                  <source>Blood</source>
                  <year>2014</year>
                  <volume>124</volume>
                  <fpage>2698</fpage>
                  <lpage>2704</lpage>
                  <pub-id pub-id-type="doi">10.1182/blood-2014-05-574889</pub-id>
                  <pub-id pub-id-type="pmid">25139356</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling</article-title>
                  <source>Oncotarget</source>
                  <year>2017</year>
                  <volume>8</volume>
                  <fpage>17763</fpage>
                  <lpage>17770</lpage>
                  <pub-id pub-id-type="doi">10.18632/oncotarget.14846</pub-id>
                  <pub-id pub-id-type="pmid">28148900</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Evans</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Sano</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Walsh</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Cardiovascular Disease, Aging, and Clonal Hematopoiesis</article-title>
                  <source>Annu Rev. Pathol.</source>
                  <year>2020</year>
                  <volume>15</volume>
                  <fpage>419</fpage>
                  <lpage>438</lpage>
                  <pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-012419-032544</pub-id>
                  <pub-id pub-id-type="pmid">31689371</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Makishima</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dynamics of clonal evolution in myelodysplastic syndromes</article-title>
                  <source>Nat. Genet</source>
                  <year>2017</year>
                  <volume>49</volume>
                  <fpage>204</fpage>
                  <lpage>212</lpage>
                  <pub-id pub-id-type="doi">10.1038/ng.3742</pub-id>
                  <pub-id pub-id-type="pmid">27992414</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Tavana</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Gu</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>p53 modifications: exquisite decorations of the powerful guardian</article-title>
                  <source>J. Mol. Cell Biol.</source>
                  <year>2019</year>
                  <volume>11</volume>
                  <fpage>564</fpage>
                  <lpage>577</lpage>
                  <pub-id pub-id-type="doi">10.1093/jmcb/mjz060</pub-id>
                  <pub-id pub-id-type="pmid">31282934</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <mixed-citation publication-type="other">Sano, S. et al. TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. <italic>JCI Insight</italic><bold>6</bold>, (2021).</mixed-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van Egeren</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms</article-title>
                  <source>Cell Stem Cell</source>
                  <year>2021</year>
                  <volume>28</volume>
                  <fpage>514</fpage>
                  <lpage>523.e519</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.stem.2021.02.001</pub-id>
                  <pub-id pub-id-type="pmid">33621486</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bisserier</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cell-Free Mitochondrial DNA as a Potential Biomarker for Astronautsâ Health</article-title>
                  <source>J. Am. Heart Assoc.</source>
                  <year>2021</year>
                  <volume>10</volume>
                  <fpage>e022055</fpage>
                  <pub-id pub-id-type="doi">10.1161/JAHA.121.022055</pub-id>
                  <pub-id pub-id-type="pmid">34666498</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cucinotta</surname>
                      <given-names>FA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Space radiation and cataracts in astronauts</article-title>
                  <source>Radiat. Res</source>
                  <year>2001</year>
                  <volume>156</volume>
                  <fpage>460</fpage>
                  <lpage>466</lpage>
                  <pub-id pub-id-type="doi">10.1667/0033-7587(2001)156[0460:SRACIA]2.0.CO;2</pub-id>
                  <pub-id pub-id-type="pmid">11604058</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chylack</surname>
                      <given-names>LT</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>NASA study of cataract in astronauts (NASCA). Report 1: Cross-sectional study of the relationship of exposure to space radiation and risk of lens opacity</article-title>
                  <source>Radiat. Res</source>
                  <year>2009</year>
                  <volume>172</volume>
                  <fpage>10</fpage>
                  <lpage>20</lpage>
                  <pub-id pub-id-type="doi">10.1667/RR1580.1</pub-id>
                  <pub-id pub-id-type="pmid">19580503</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Belobrajdic</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Melone</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Diaz-Artiles</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Planetary extravehicular activity (EVA) risk mitigation strategies for long-duration space missions</article-title>
                  <source>NPJ Microgravity</source>
                  <year>2021</year>
                  <volume>7</volume>
                  <fpage>16</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41526-021-00144-w</pub-id>
                  <pub-id pub-id-type="pmid">33980866</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bolton</surname>
                      <given-names>KL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cancer therapy shapes the fitness landscape of clonal hematopoiesis</article-title>
                  <source>Nat. Genet</source>
                  <year>2020</year>
                  <volume>52</volume>
                  <fpage>1219</fpage>
                  <lpage>1226</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41588-020-00710-0</pub-id>
                  <pub-id pub-id-type="pmid">33106634</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moliterno</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Braunstein</surname>
                      <given-names>EM</given-names>
                    </name>
                  </person-group>
                  <article-title>The roles of sex and genetics in the MPN</article-title>
                  <source>Int Rev. Cell Mol. Biol.</source>
                  <year>2022</year>
                  <volume>366</volume>
                  <fpage>1</fpage>
                  <lpage>24</lpage>
                  <pub-id pub-id-type="doi">10.1016/bs.ircmb.2021.08.001</pub-id>
                  <pub-id pub-id-type="pmid">35153002</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Karantanos</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden</article-title>
                  <source>Blood Adv.</source>
                  <year>2020</year>
                  <volume>4</volume>
                  <fpage>2567</fpage>
                  <lpage>2576</lpage>
                  <pub-id pub-id-type="doi">10.1182/bloodadvances.2019001407</pub-id>
                  <pub-id pub-id-type="pmid">32542392</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
